SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7241)10/24/2002 10:44:11 PM
From: Biomaven  Respond to of 52153
 
Very nice (18%) move up today by KOSP from very depressed levels on the announcement of Merck KG as a partner outside the US.

Message 18151399

On the downside, I missed MEDI's depressing CC - bad news for BTRN and sounds like Flumist is delayed an unknown amount. I can't believe they saved all the bad stuff for the call instead of their release.

Peter



To: Biomaven who wrote (7241)10/24/2002 11:33:37 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 52153
 
Peter,

Large part of this broad arthritis population is Osteoarthritis. So far only symptoms are treated: swelling and pain, while very little can be done for disease itself.

Also, while RA is consider to be mainly immunology origin, OA is multiple factors disease and with difficult to approach. So, multi-$MM drug will come from OA not RA, imo.

Miljenko

PS: Once-a-month SC injection can (and will be) be more acceptable than daily oral regime.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News